HUP0402566A3 - C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them - Google Patents

C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them

Info

Publication number
HUP0402566A3
HUP0402566A3 HU0402566A HUP0402566A HUP0402566A3 HU P0402566 A3 HUP0402566 A3 HU P0402566A3 HU 0402566 A HU0402566 A HU 0402566A HU P0402566 A HUP0402566 A HU P0402566A HU P0402566 A3 HUP0402566 A3 HU P0402566A3
Authority
HU
Hungary
Prior art keywords
indazolylamino
pyrrolotriazines
modified
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0402566A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUP0402566A2 publication Critical patent/HUP0402566A2/hu
Publication of HUP0402566A3 publication Critical patent/HUP0402566A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/009—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone characterised by the material treated
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/4584—Coating or impregnating of particulate or fibrous ceramic material
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00793—Uses not provided for elsewhere in C04B2111/00 as filters or diaphragms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Photoreceptors In Electrophotography (AREA)
HU0402566A 2001-11-14 2002-11-12 C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them HUP0402566A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301401P 2001-11-14 2001-11-14
PCT/US2002/036528 WO2003042172A2 (en) 2001-11-14 2002-11-12 C-5 modified indazolylpyrrolotriazines

Publications (2)

Publication Number Publication Date
HUP0402566A2 HUP0402566A2 (hu) 2005-03-29
HUP0402566A3 true HUP0402566A3 (en) 2009-01-28

Family

ID=23300880

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402566A HUP0402566A3 (en) 2001-11-14 2002-11-12 C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them

Country Status (24)

Country Link
US (2) US6908916B2 (hu)
EP (1) EP1446401B1 (hu)
JP (1) JP4301440B2 (hu)
KR (1) KR20050044441A (hu)
CN (1) CN1615306A (hu)
AR (1) AR037368A1 (hu)
AT (1) ATE524462T1 (hu)
BR (1) BR0214112A (hu)
CA (1) CA2467068A1 (hu)
ES (1) ES2370709T3 (hu)
HR (1) HRP20040422A2 (hu)
HU (1) HUP0402566A3 (hu)
IL (1) IL161616A0 (hu)
IS (1) IS7243A (hu)
MX (1) MXPA04004492A (hu)
NO (1) NO20041983L (hu)
NZ (1) NZ533034A (hu)
PE (1) PE20030712A1 (hu)
PL (1) PL368909A1 (hu)
RU (1) RU2004117549A (hu)
TW (1) TW200300350A (hu)
UY (1) UY27540A1 (hu)
WO (1) WO2003042172A2 (hu)
ZA (1) ZA200403694B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
PL373371A1 (en) 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
CN102093363B (zh) * 2002-04-23 2016-12-07 布里斯托尔-迈尔斯斯奎布公司 可用作激酶抑制剂的吡咯并三嗪苯胺化合物
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
KR20050099525A (ko) 2003-02-05 2005-10-13 브리스톨-마이어스 스큅 컴퍼니 피롤로트리아진 키나제 억제제의 제조 방법
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
ATE421510T1 (de) 2005-03-28 2009-02-15 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CA2631741C (en) 2005-12-02 2014-01-28 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
KR20120065321A (ko) * 2009-07-28 2012-06-20 우베 고산 가부시키가이샤 피롤로〔2,3-ｄ〕피리미딘 유도체
CN102627647A (zh) * 2012-03-20 2012-08-08 南京药石药物研发有限公司 4-氯-5-甲基-1H-吡咯并[2,1-f][1,2,4]三嗪的合成方法
WO2014115171A1 (en) * 2013-01-24 2014-07-31 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
JP6473146B2 (ja) 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピロロトリアジンキナーゼ阻害剤
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
PT778277E (pt) 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
PL373371A1 (en) * 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
EP1446401A2 (en) 2004-08-18
UY27540A1 (es) 2003-07-31
PE20030712A1 (es) 2003-08-21
HRP20040422A2 (en) 2005-04-30
KR20050044441A (ko) 2005-05-12
US20030186983A1 (en) 2003-10-02
PL368909A1 (en) 2005-04-04
NZ533034A (en) 2004-11-26
CN1615306A (zh) 2005-05-11
US6908916B2 (en) 2005-06-21
EP1446401A4 (en) 2006-04-12
ES2370709T3 (es) 2011-12-22
JP4301440B2 (ja) 2009-07-22
EP1446401B1 (en) 2011-09-14
BR0214112A (pt) 2004-09-14
ATE524462T1 (de) 2011-09-15
IL161616A0 (en) 2004-09-27
AR037368A1 (es) 2004-11-03
CA2467068A1 (en) 2003-05-22
NO20041983D0 (no) 2004-05-13
WO2003042172A2 (en) 2003-05-22
ZA200403694B (en) 2006-06-28
JP2005509030A (ja) 2005-04-07
RU2004117549A (ru) 2006-01-10
MXPA04004492A (es) 2004-08-11
NO20041983L (no) 2004-06-24
HUP0402566A2 (hu) 2005-03-29
IS7243A (is) 2004-04-30
TW200300350A (en) 2003-06-01
US20050209235A1 (en) 2005-09-22
WO2003042172A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
HUP0301722A3 (en) Pyrimidine derivatives, pharmaceutical compositions containing them and their use
IL164376A0 (en) Ox4or binding agents, their preparation and pharmaceutical compositions containing them
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
IL151209A0 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
HUP0401898A3 (en) 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
HUP0302959A3 (en) Non-imidazole aryloxyalkylamines, pharmaceutical compositions containing them and their use
HUP0402003A3 (en) Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0401900A3 (en) 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
IL158898A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished